Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : and Indivumed announce strategic drug discovery collaboration on precision medicine for colorectal cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2019 | 10:42am EDT

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer ('CRC').

The collaboration, which runs for an initial term of two years, will combine Evotec's proprietary bioinformatics analysis platform 'PanHunter' as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed's true multi-omics cancer database 'IndivuType'. The goal of this precision medicine collaboration is to deliver highly effective and durable treatments with clear strategies for CRC patient stratification.

Indivumed's commitment to generating high quality and extensive cancer patient data is synergistic to Evotec's expertise in analysing multi-omics data and developing novel platforms to aid the discovery of first-in-class clearly differentiated small molecule and antibody therapeutics.

Under the terms of the agreement, Evotec has made an undisclosed upfront payment to Indivumed for access to the CRC patient cohort of the IndivuType database. Both parties will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be responsible for subsequent partnering of the programmes and/or the platform.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: 'Evotec is very pleased to partner with Indivumed, who is truly dedicated to developing precision medicine in oncology by generating the most comprehensive multi-omics patient database in oncology that is differentiated from previous datasets due to the higher patient numbers and the application of rigorous quality standards. The access to IndivuType will allow us to identify targets that are matched to CRC subpopulations which have been categorised due to molecular phenotypes and are thus expected to deliver more effective and durable drugs'.

Prof. Dr Hartmut Juhl, Chief Executive Officer of Indivumed, said: 'IndivuType is the only true multi-omics database available in the world, enabling break-through insights that lead to new cancer solutions. Our partnership with Evotec fits well with realising our vision of using the multi-omics data within IndivuType to generate new precision medicine therapeutics. We are excited about the prospect of identifying novel drug targets and biomarkers that will help advance and transform CRC patient care. Our team will be attending ASCO where clinicians and researchers will have the opportunity to explore more about IndivuType'.

About Colorectal Cancer ('CRC')

Colorectal cancer, a cancer that starts in the colon or rectum is the third most common malignancy and the fourth leading cause of cancer-related deaths worldwide. Rapid increases in both CRC incidence and mortality are now observed in Eastern Europe, Asia, and South America. In contrast, CRC incidence and mortality rates have been stabilising or declining in the USA, Australia, New Zealand, and several Western European countries. The reasons for decreasing trends in CRC mortality are knowledge of risk factors, early detection and prevention, and improvements in perioperative care. Since the five-year overall survival for patients with metastatic CRC is poor (14%), there yet remains a strong need to develop new therapeutics for this disease.

About IndivuType

IndivuType, the world's first true multi-omics database for individualised cancer therapy uses the highest quality cancer biospecimens that ultimately produces highest quality data to enable novel discoveries in cancer biology in the post-genomics era. Indivumed is deeply committed to the quality of the IndivuType ecosystem along every step of the process, starting with stringent SOP-driven sample collection procedures combined with thorough validation of clinical information and data integrity. IndivuType's powerful database can forge a path to accelerate clinical trials, enable robust protocol design, and generate insights for precision oncology treatment and improved patient outcomes.

ABOUT INDIVUMED GMBH

Indivumed, a global oncology research company based in Hamburg, Germany, has established the world's leading multi-omics cancer database and biobank. Our proprietary sample collection processes and technology help preserve the integrity of RNA, DNA, and proteins as they existed in the human body. IndivuType, our cancer database, contains vast amounts of genomics, transcriptomics, proteomics, phospho-proteomics and immuno-phenotype imaging information together with clinical and outcome data, making it a unique resource for cancer research in the post-genomics era. Coupled with cutting-edge data analytics, the cancer database can provide deep insights into the underlying mechanisms of a patient's cancer, addressing important needs in translational research and molecular diagnostics to ultimately deliver personalised cancer healthcare. www.indivumed.com

Contact:

Tel: 00+1+703.519.1600

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
07/15EVOTEC : Expands its ipsc discovery platform
EQ
07/12EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
07/08Eurofins to slow pace of M&A, expand in emerging markets
RE
07/08EVOTEC : and venture capital consortium form 'Breakpoint Therapeutics GmbH'
AQ
07/08EVOTEC : And venture capital consortium form 'breakpoint therapeutics gmbh'
EQ
07/04EVOTEC : completes acquisition of Just Biotherapeutics
AQ
07/03EVOTEC SE : Notification and public disclosure of transactions by persons
EQ
07/03EVOTEC : Completes acquisition of just biotherapeutics
EQ
06/28EVOTEC SE : Release according to Article 41 of the WpHG [the German Securities T..
EQ
06/27EVOTEC : places first Schuldschein worth EUR 250 m
AQ
More news
Financials (EUR)
Sales 2019 417 M
EBIT 2019 76,6 M
Net income 2019 55,3 M
Finance 2019 64,1 M
Yield 2019 -
P/E ratio 2019 64,7x
P/E ratio 2020 65,0x
EV / Sales2019 9,09x
EV / Sales2020 8,16x
Capitalization 3 852 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 26,2  €
Last Close Price 25,8  €
Spread / Highest target 27,9%
Spread / Average Target 1,51%
Spread / Lowest Target -22,5%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE48.34%4 217
IQVIA HOLDINGS INC36.35%31 409
LONZA GROUP30.00%25 111
CELLTRION, INC.--.--%20 827
INCYTE CORPORATION27.99%17 419
EXACT SCIENCES CORPORATION84.14%15 001